Dual-functional drug liposomes in treatment of resistant cancers

Area of Science:

• Nanomedicine
• Drug Delivery Systems
• Cancer Therapy

Background:

• Multidrug resistance (MDR) and systemic toxicity significantly limit chemotherapy efficacy.
• Liposomal drug delivery systems have evolved through three generations, reducing toxicity but not fully resolving MDR.
• MDR in cancer remains a critical challenge in effective treatment strategies.

Purpose of the Study:

• To review dual-functional drug liposomes as a strategy to overcome multidrug resistance in cancer.
• To explore the mechanisms by which dual-functional liposomes combat resistant cancer phenotypes.
• To assess the potential of dual-functional liposomes for future clinical applications.

Main Methods:

• Review of literature on liposome generations and their impact on drug delivery and toxicity.
• Analysis of mechanisms employed by dual-functional liposomes against resistant cancer cells.
• Examination of the extended functions of drug carriers in overcoming MDR.

Main Results:

• Dual-functional drug liposomes are phospholipid vesicles with dual roles: drug delivery and carrier-mediated therapeutic effects.
• These liposomes circumvent drug efflux mediated by adenosine triphosphate binding cassette (ABC) transporters.
• They also target cancer stem cells, mitochondria, and regulate cellular processes like apoptosis and autophagy.

Conclusions:

• Dual-functional drug liposomes show significant potential in overcoming cancer multidrug resistance.
• Their extended functions, beyond basic drug delivery, are key to their efficacy.
• Further clinical validation is warranted to fully realize the therapeutic promise of these advanced liposomes.